Study of ADI-PEG20 with chemo for aggressive prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This study tests a combination of three drugs—ADI-PEG20, carboplatin, and cabazitaxel—in men with aggressive variant prostate cancer that has stopped responding to hormone therapy. The goal is to see if this combination can shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have an aggressive type of prostate cancer (like small cell or with fast growth).
- You can have had up to one prior chemo treatment, but not carboplatin, cisplatin, or cabazitaxel.
- Your cancer must be growing despite low testosterone (castration-resistant).
- Your kidney, liver, and blood counts need to be good enough for the study drugs.
- You must be willing to use birth control if you have a partner who could become pregnant.
- You cannot have serious medical conditions (like uncontrolled infections or recent heart attack).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at combining hormone therapy with either chemotherapy (docetaxel), a targeted pill (like abiraterone or enzalutamide), or radiation to the prostate tumor for men whose prostate cancer has spread but is still sensitive to hormones. The goal is to see which approach works best for controlling the cancer.
This trial tests whether a combination of three new drugs (SHR3680, HS-20093, and SHR2554) can help slow or stop prostate cancer growth. It is for men who are already on hormone therapy and whose PSA level is still rising.
This Phase 2 trial tests pembrolizumab together with carboplatin and cabazitaxel in men with aggressive, metastatic prostate cancer that has become resistant to hormone therapy. It may help shrink tumors and improve outcomes for people with hard-to-treat forms of prostate cancer.
This trial tests if adding docetaxel chemotherapy helps men whose PSA hasn't dropped enough after at least 6 months of standard hormone therapy (ADT) plus an ARPI pill (like abiraterone or enzalutamide) for metastatic prostate cancer that still responds to hormones.
This trial tests a new targeted cancer drug (PDS01ADC) combined with standard treatments docetaxel and abiraterone for men with advanced prostate cancer that has spread. The goal is to see if the combination is safe and whether it can control cancer better than current approaches.
This study tests several new drug combinations for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It aims to find better ways to control the disease and improve outcomes.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.